UK: +44 (0)207 989 0813
NA: +1 646 896 3065
AU +61 2 9280 0700
action@proactiveinvestors.com

Pharmaxis Ltd

02:12 26 Mar 2019

Pharmaxis prepares for advisory committee meeting on use of Bronchitol in the US

Pharmaxis Ltd (ASX:PXS) is preparing for an important meeting that will make recommendations on the possible use of its Bronchitol® product for adult cystic fibrosis patients in the United States.

The company is supporting its licensee Chiesi Group in preparing for a meeting with the Pulmonary-Allergy Drugs Advisory Committee (PADAC) which will take place in May.

Chiesi, which is responsible for the regulatory approval process, has been advised by the US Food and Drug Administration (FDA) that the PADAC meeting will take place in the US on May 8.

READ: Pharmaxis sees progress in Boehringer Ingelheim's clinical trial in patients with NASH

Pharmaxis is an Australian pharmaceutical research company focused on inflammation and fibrosis. It has a portfolio of products at various stages of development and approval.

One of these products, Bronchitol, for treatment of cystic fibrosis, is marketed in Europe, Russia and Australia and the company is seeking to market it in the large US market.

As part of this process, Chiesi resubmitted the Bronchitol New Drug Application to the FDA in December of 2018.

Used in treatment of cystic fibrosis patients

Bronchitol is a precision spray-dried form of mannitol, delivered to the lungs by a specially designed, portable inhaler.

It works by rehydrating the airway/lung surface and promoting a productive cough. Bronchitol is used for the treatment of cystic fibrosis patients.

Price: 0.115

Market Cap: $45.39 m

1 Year Share Price Graph



Share Information

Code:	PXS	
Listing:	ASX	
52 week	**High**	**Low**
	0.305	**0.105**
Sector:	**Pharma & Biotech**	
Website:	**www.pharmaxis.com.au**	

Company Synopsis:

Pharmaxis Ltd (ASX:PXS) is a specialty pharmaceutical company focused on the development of new products for the diagnosis and treatment of chronic respiratory and immune disorders.

action@proactiveinvestors.com

READ: Pharmaxis begins phase one clinical trial of compound targeting pancreatic cancer

PADAC, which is convened by the FDA, reviews and evaluates available data concerning the safety and effectiveness of marketed and investigational human drug products for use in the treatment of pulmonary disease and diseases with allergic and/or immunologic mechanisms.

Through this process, PADAC makes appropriate recommendations to the Commissioner of Food and Drugs in the US.

The committee comprises a core of 11 voting members including the chair.

These members are selected by the Commissioner from among authorities knowledgeable in the fields of pulmonary medicine, allergy, clinical immunology, and epidemiology or statistics.

From time to time, reference may be made in our marketing materials to prior articles and opinions we have published. These references may be selective, may reference only a portion of an article or recommendation, and are likely not to be current. As markets change continuously, previously published information and data may not be current and should not be relied upon.

The Site does not, and is not intended to, provide investment, tax, accounting, legal or insurance advice, and is not and should not be construed as providing any of the foregoing. You should consult an attorney or other relevant professional regarding your specific legal, tax, investment or other needs as tailored to your specific situation.

In exchange for publishing services rendered by the Company on behalf of Pharmaxis Ltd named herein, including the promotion by the Company of Pharmaxis Ltd in any Content on the Site, the Company receives from said issuer annual aggregate cash compensation in the amount up to Twenty Five Thousand dollars ($25,000).